Implementation of a dual platelet inventory in a tertiary hospital during the COVID-19 pandemic enabling cold-stored apheresis platelets for treatment of actively bleeding patients.
bleeding
blood preparedness
cold-stored platelets
dual inventory
inventory management
pandemic
platelet concentrate
platelet transfusion
storage of blood components
surgery
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
01
05
2022
received:
04
02
2022
accepted:
02
06
2022
pubmed:
23
6
2022
medline:
30
7
2022
entrez:
22
6
2022
Statut:
ppublish
Résumé
To increase preparedness and mitigate the risk of platelet shortage without increasing the number of collections, we introduced a dual platelet inventory with cold-stored platelets (CSP) with 14-days shelf life for actively bleeding patients during the COVID-19 pandemic. We collected apheresis platelet concentrates with blood type O or A. All patients receiving CSP units were included in a quality registry. Efficacy was evaluated by total blood usage and laboratory analysis of platelet count, hemoglobin, and TEG 6s global hemostasis assay. Feasibility was evaluated by monitoring inventory and a survey among laboratory staff. From 17 March, 2020, to 31 December, 2021, we produced 276 CSP units and transfused 186 units to 92 patients. Main indication for transfusion was surgical bleeding (88%). No transfusion reactions were reported. 24-h post-transfusion patient survival was 96%. Total outdate in the study period was 33%. The majority (75%) of survey respondents answered that they had received sufficient information and training before CSP was implemented. Lack of information about bleeding status while issuing platelets, high workload, and separate storage location was described as main reasons for outdates. CSP with 14-days shelf life is a feasible alternative for the treatment of patients with bleeding. Implementation of a dual platelet inventory requires thorough planning, including information and training of clinical and laboratory staff, continuous follow-up of practice and patients, and an easy-to-follow algorithm for use of CSP units. A dual platelet inventory may mitigate the risk of platelet shortage during a pandemic situation.
Sections du résumé
BACKGROUND
To increase preparedness and mitigate the risk of platelet shortage without increasing the number of collections, we introduced a dual platelet inventory with cold-stored platelets (CSP) with 14-days shelf life for actively bleeding patients during the COVID-19 pandemic.
STUDY DESIGN AND METHODS
We collected apheresis platelet concentrates with blood type O or A. All patients receiving CSP units were included in a quality registry. Efficacy was evaluated by total blood usage and laboratory analysis of platelet count, hemoglobin, and TEG 6s global hemostasis assay. Feasibility was evaluated by monitoring inventory and a survey among laboratory staff.
RESULTS
From 17 March, 2020, to 31 December, 2021, we produced 276 CSP units and transfused 186 units to 92 patients. Main indication for transfusion was surgical bleeding (88%). No transfusion reactions were reported. 24-h post-transfusion patient survival was 96%. Total outdate in the study period was 33%. The majority (75%) of survey respondents answered that they had received sufficient information and training before CSP was implemented. Lack of information about bleeding status while issuing platelets, high workload, and separate storage location was described as main reasons for outdates.
DISCUSSION
CSP with 14-days shelf life is a feasible alternative for the treatment of patients with bleeding. Implementation of a dual platelet inventory requires thorough planning, including information and training of clinical and laboratory staff, continuous follow-up of practice and patients, and an easy-to-follow algorithm for use of CSP units. A dual platelet inventory may mitigate the risk of platelet shortage during a pandemic situation.
Identifiants
pubmed: 35732490
doi: 10.1111/trf.16988
pmc: PMC9349781
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S193-S202Informations de copyright
© 2022 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Transfusion. 1976 Jan-Feb;16(1):20-3
pubmed: 1251454
Transfusion. 2017 Dec;57(12):2836-2844
pubmed: 28880362
Transfusion. 1997 Jan;37(1):18-24
pubmed: 9024485
Transfusion. 2016 Mar;56 Suppl 1:S76-84
pubmed: 27001365
Transfusion. 2020 Jul;60(7):1544-1551
pubmed: 32319702
Lancet Haematol. 2020 Oct;7(10):e756-e764
pubmed: 32628911
Transfusion. 2016 Jun;56(6):1320-8
pubmed: 26853912
Transfusion. 2020 Mar;60(3):613-621
pubmed: 32017135
J Proteome Res. 2021 May 7;20(5):2251-2265
pubmed: 33780259
Transfusion. 1977 May-Jun;17(3):255-60
pubmed: 867467
Anesthesiology. 2020 Dec 1;133(6):1173-1183
pubmed: 32902572
Transfusion. 2019 Aug;59(8):2652-2661
pubmed: 31150571
J Trauma Acute Care Surg. 2014 Sep;77(3 Suppl 2):S88-93
pubmed: 25159368
Vox Sang. 2021 May;116 Suppl 1:5-188
pubmed: 34060100
Transfusion. 1974 Jul-Aug;14(4):328-30
pubmed: 4843240
Transfusion. 2019 Apr;59(S2):1479-1489
pubmed: 30980761
Transfusion. 1973 Mar;13(2):61-8
pubmed: 4695593
Shock. 2014 May;41 Suppl 1:54-61
pubmed: 24169210
Transfusion. 2021 Jul;61 Suppl 1:S22-S31
pubmed: 34269432
Vox Sang. 2018 Apr 6;:
pubmed: 29633290
Transfusion. 2021 Jan;61(1):72-77
pubmed: 33029791
Haematologica. 2019 Jan;104(1):207-214
pubmed: 30115655
Transfus Med Rev. 2020 Oct;34(4):221-226
pubmed: 33039263
Br J Haematol. 2017 Jul;178(1):119-129
pubmed: 28580719
Transfusion. 2022 Aug;62 Suppl 1:S193-S202
pubmed: 35732490